Detail Image
Bio-Maltose 50mg/ml Injection
50mg ,

Each Vial Contains

Each ml contains: Iron as Ferric Carboxymaltose



Ferric Carboxymaltose 500mg/10ml


  1. Effectively used to cure Iron Deficiency Anemia
  2. It is a Novel Iron Complex
  3. It consists of the Ferric Hydroxide core stabilised by the carbohydrate shell that allows control delivery of the iron.
  4. Ferric carboxymaltose is found to be the better and more efficient in alternate to Iron Sucrose in the treatment of postpartum anaemia
  5. It has the advantage of single-dose with lower side effects



Ferric carboxymaltose is a macromolecular ferric hydroxide carbohydrate complex that allows the controlled delivery of iron within the cells of the reticuloendothelial system and delivers subsequently to the transferrin and ferritin – the iron-binding proteins, with the lesser risk of releasing a large quantity of ionic iron in the serum.

Key Features

  1. Each 10 mL vial contains ferric carboxymaltose corresponding to 500 mg iron.
  2. Solution for injection/infusion. Dark brown, non-transparent, aqueous solution.
  3. No particular human hazards are revealed in the preclinical data based on conventional studies of repeat dose toxicity, safety pharmacology, and genotoxicity.



Bio-Maltose is indicated for the treatment of iron deficiency when;

– Oral iron preparations are ineffective.

– Oral iron preparations cannot be used.

– There is a clinical need to deliver iron rapidly.

The diagnosis of iron deficiency must be based on laboratory tests.


Bio-Maltose should only be administered when staff trained to evaluate and manage anaphylactic reactions is immediately available, in an environment where full resuscitation facilities can be assured. The patient should be observed for adverse effects for at least 30 minutes following each Bio-Maltose administration.


Follow the step-wise approach

Step 1 Determination of the iron need

The individual iron need for repletion using Bio-Maltose is determined based on the patient’s body weight and haemoglobin (Hb) level.

Hb Patient body weight
g/dL mmol/L below 35 kg 35 kg to <70 kg 70 kg and above
<10 <6.2 500 mg 1,500 mg 2,000 mg
10 to <14 6.2 to <8.7 500 mg 1,000 mg 1,500 mg
≥14 ≥8.7 500 mg 500 mg 500 mg


Step 2 Calculation and administration of the maximum individual iron dose(s)

Based on the iron need determined above, the appropriate dose(s) of Bio-Maltose should be administered taking into consideration the following:

A single Bio-Maltose administration should not exceed:

  1. 15 mg iron/kg body weight (for administration by intravenous injection) or 20 mg iron/kg body weight (for administration by intravenous infusion)
  2. 1,000 mg of iron (20 mL Bio-Maltose)

The maximum recommended cumulative dose of Bio-Maltose is 1,000 mg of iron (20 mL Bio-Maltose) per week.

Step 3: Post-iron repletion assessments

The clinician should perform a re-assessment based on the individual patient’s condition. The Hemoglobin level should be re-assessed no earlier than four weeks post final Bio-Maltose administration to allow adequate time for erythropoiesis and iron utilisation. If the patient requires further iron repletion, the iron need should be recalculated.


  1. Known severe hypersensitivity to other parenteral iron products.
  2. Anaemia not attributed to iron deficiency, e.g. other microcytic anaemia.
  3. Evidence of iron overload or disturbances in the utilisation of iron.



Hypersensitivity reactions

Parenterally administered iron preparations can cause hypersensitivity reactions including serious and potentially fatal anaphylactic/anaphylactoid reactions. Hypersensitivity reactions have also been reported after previously uneventful doses of parenteral iron complexes. 

The risk is enhanced for patients with known allergies, including drug allergies, including patients with a history of severe asthma, eczema, or other atopic allergies.

Risks are higher for patients with Rheumatoid Arthritis and systemic lupus erythematosus.

Hepatic or renal impairment

In patients with liver dysfunction, parenteral iron should only be administered after careful benefit/risk assessment. Parenteral iron administration should be avoided in patients with hepatic dysfunction where iron overload is a precipitating factor, in particular Porphyria Cutanea Tarda (PCT). Careful monitoring of iron status is recommended to avoid iron overload.

No safety data on hemodialysis-dependent chronic kidney disease patients receiving single doses of more than 200 mg iron are available.


Parenteral iron must be used with caution in case of acute or chronic infection, asthma, eczema, or atopic allergies. It is recommended that the treatment with Bio-Maltose be stopped in patients with ongoing bacteremia. Therefore, a benefit/risk evaluation has to be performed in patients with chronic infection, taking into account the suppression of erythropoiesis.

Pediatric population

The use of Bio-Maltose has not been studied in children.